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Abstract
Objective
Elevated γ-Glutamyltransferase serum levels are associated with increased risk of overall
cancer incidence and several site-specific malignancies. In the present prospective study
we report on the associations of serum γ-Glutamyltransferase with the risk of breast cancer
in a pooled population-based cohort considering established life style risk factors.
Methods
Two cohorts were included in the present study, i.e. the Vorarlberg (n = 97,268) and the Mal-
moe cohort (n = 9,790). Cox proportional hazards regression models were fitted to estimate
HRs for risk of breast cancer.
Results
In multivariate analysis adjusted for age, bodymass index and smoking status, womenwith γ-
Glutamyltransferase levels in the top quartile were at significantly higher risk for breast cancer
compared to women in the lowest quartile (HR 1.21, 95%CI 1.09 to 1.35; p = 0.005). In the sub-
group analysis of theMalmoe cohort, γ-Glutamyltransferase remained an independent risk factor
for breast cancer when additionally considering alcohol intake. A statistically significant increase
in risk was seen in womenwith γ-Glutamyltransferase-levels in the top versus lowest quartile in a
multivariate model adjusted for age, bodymass index, smoking status, physical activity, parity,
oral contraceptive-use and alcohol consumption (HR 1.37, 95%CI 1.11–1.69, p = 0.006).
Conclusion
Our findings identified γ-Glutamyltransferase as an independent risk factor for breast cancer
beyond the consumption of alcohol and other life style risk factors.
PLOS ONE | DOI:10.1371/journal.pone.0149122 February 10, 2016 1 / 11
OPEN ACCESS
Citation: Preyer O, Johansen D, Holly J, Stocks T,
Pompella A, Nagel G, et al. (2016) γ-
Glutamyltransferase and Breast Cancer Risk Beyond
Alcohol Consumption and Other Life Style Factors –
A Pooled Cohort Analysis. PLoS ONE 11(2):
e0149122. doi:10.1371/journal.pone.0149122
Editor: Chin-Kuo Chang, Institute of Psychiatry,
UNITED KINGDOM
Received: August 9, 2015
Accepted: January 27, 2016
Published: February 10, 2016
Copyright: © 2016 Preyer et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
γ-Glutamyltransferase (GGT) is a key enzyme in glutathione (glutamyl-cysteinyl-glycine;
GSH) metabolism. It catalyses the degradation of extracellular GSH, thus providing component
amino acids that are then available for further intracellular GSH production. GSH functions as
the major antioxidant of the cell, neutralizing reactive oxygen compounds and free radicals [1].
GSH catabolism is modulated uniquely by the enzyme GGT. It hydrolyses the γ-Glutamyl
bond between glutamate and cysteine. Oxidative stress conditions can induce the expression of
GGT as shown in experimental studies [2–4]. On the other hand, it has been repeatedly shown
that GGT activity itself can give rise to prooxidant reactions [5].
For decades the determination of serum GGT levels has represented a reliable marker for
evaluation of liver dysfunction, particularly in connection with alcohol consumption [1]. How-
ever, recent epidemiologic studies have shown elevated GGT to independently influence mor-
bidity and mortality from causes other than liver disease [6–9]. GGT plays a role in major
diseases such as diabetes, metabolic syndrome, and cardiovascular disease [7, 10]. Also, ele-
vated GGT levels are implicated in increased risk of overall cancer incidence and several site-
specific malignancies in women and men [11, 12]. Strasak et al. showed an increased risk of
cancer in digestive organs, respiratory system/intrathoracic organs, urinary organs (in men),
and lymphoid and hematopoietic cancers (in women). Furthermore, in this study GGT levels
significantly impacted the risk for pooled female malignancies (breast and female genital malig-
nancies), although the specific female tumour sites were not discriminated [11]. With respect
to breast cancer, two previous studies have focused on the association of GGT levels and breast
cancer risk. Fentiman et al. identified high GGT levels to positively correlate with breast cancer
incidence in premenopausal patients only, while Hemelrijck et al. established GGT as a breast
cancer risk factor in general [13, 14]. Interpretation of these studies is hampered by lack or lim-
ited knowledge on established breast cancer risk factors, particularly with respect to life style
factors. Besides, a recent study has investigated the prognostic impact of pre-therapeutic GGT
levels in primary metastatic breast cancer patients and established GGT serum levels as a novel
prognostic factor [15].
In this prospective study we report on the associations of serum GGT levels with the risk of
breast cancer in a pooled population-based cohort of a total of 107,058 women considered
established risk factors for breast cancer including age, body mass index (BMI), smoking status,
physical activity, parity, oral contraceptive (OC)-use and alcohol consumption. Two cohorts
were included into the present study, i.e. the Vorarlberg cohort, Austria’s westernmost federal
state, and the Malmoe cohort, Sweden’s third largest city. Cross-sectional correlates of GGT
with various breast cancer risk factors were performed in the Malmoe subgroup.
Materials and Methods
Study populations
The Vorarlberg Health Monitoring and Promotion Program (VHM&PP) is one of the world´s
largest population-based risk factor surveillance programs. The cohort was initiated in 1985
and is conducted by the Agency for Social and Preventive Medicine in Vorarlberg, the western-
most federal state of Austria. All adults in the region were invited to participate through a com-
bination of different measures including written invitations, television, radio, and newspaper
reports. Participants were enrolled continuously from 1985 through 2004. Follow-up was
determined based on subject’s home addresses using a recall system of written biennial re-invi-
tation letters. Loss to follow-up (e.g., due to migration) was<1%.
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Sociodemographic data were recorded, and trained local physicians and internists con-
ducted a voluntary physician examination regularly in a standardized manner. Costs were cov-
ered by the participant´s (compulsory) health insurance. A more detailed description of the
program methodology has been reported elsewhere [16].
Between 1985 and 2004, 98,995 female Vorarlberg residents (ages>18 yrs.) were enrolled in
the VHM&PP. We excluded 1,676 participants (1.7%) with missing or incomplete data on
GGT at enrolment or with history of malignancies prior to enrolment. To eliminate possible
effects of preclinical cancer by producing/altering GGT, we further excluded participants with
baseline GGT serum values>600 units/L (n = 51), resulting in a total of 97,268 women eligible
for analyses for the current investigation.
The second cohort included into the present study is the Malmoe Preventive Project (MPP).
This project was set up in 1974 as an integrated institute within the Department of Medicine at
Malmoe University Hospital, Sweden. The main objective of the MPP was to screen a middle-
aged population for risk factors such as cardiovascular diseases, diabetes mellitus and alcohol-
ism, and thereby develop methods–on an individual patient basis–for early detection, health
education and prevention of a number of diseases and risk factors [17]. Captured anamnestic
data included e.g. age, BMI, smoking status, physical activity, parity, OC-use, alcohol con-
sumption and treatment for nervous or mental disorders. Between 1974 and 1994, complete
birth-year cohorts of registered residents in Malmoe were invited by letter to a health screening
investigation. Women born in 1926, 1928, 1930–1938, 1941 and in 1949 were invited. All
10,902 female residents were enrolled in the MPP. Exclusions were made for participants with
missing or incomplete data on GGT at enrolment, or with a history of malignancies prior to
enrolment (n = 1098). To eliminate possible effects of preclinical cancer by producing/altering
GGT, we further excluded participants with baseline GGT serum values>600 units/L (n = 14),
resulting in a total of 9,790 women eligible for analyses for the current investigation.
The participants of both cohorts signed informed consents to have personal data stored and
processed. For this study, institutional board approval was obtained by the Ethics Committees
in the respective countries (The Ethics Committee of Vorarlberg, decision 2006-6/2; The Ethics
Committee at Lund University, decision LU-828-02).
Measurement of GGT
Two central laboratories undergoing regular internal and external quality procedures enzymat-
ically determined serum GGT concentrations on blood samples in the Vorarlberg cohort. It
has been shown that GGT displays a considerable intra-individual stability and strong “track-
ing” pattern. Within 60 to 204 min after venous blood sample collection from a cubital vein,
serum was obtained by centrifugation for 15 minutes at 4000 rotations per minute. Subse-
quently, GGT concentrations were measured until 2002 at 25°C, after that at 37°C and were
given as units per Litre (U/L). A standard laboratory method, using Ƴ-glutamyl-Ƥ-nitroanilin
as a substrate, was used by Malmoe University Hospital to analyse plasma-GGTon blood sam-
ples in the Malmoe cohort [18].
For analysis all GGT measurements were recalculated to 37°C and given as U/L. According
to previously published data levels of GGT 18 U/L were regarded as normal high or elevated
[19].
Statistical analysis
Cox proportional hazards regression analysis was used to estimate hazard ratios (HRs) and
their 95% confidence intervals (CIs) for the association of GGT with breast cancer incidence.
Follow-up for a woman started at the date of her health examination and ended at invasive
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breast cancer diagnosis or at censoring. Censoring events were death, cancer diagnosis at other
site, end of study, loss to follow-up and emigration.
First, we computed univariate HRs with 95% CIs using baseline GGT levels divided into
quartiles (groups13 U/L, 14–17 U/L, 18–25 U/L and26 U/L) in the pooled Vorarlberg and
Malmoe cohort. Due to rounded measurements of GGT frequencies in the quartiles do not
match exactly 25%. Second, we fitted Cox models using GGT adjusting for age, BMI and smok-
ing status (model I). For the Malmoe cohort only, a model was computed with alcohol con-
sumption as an additional covariate, further adjusting for age, BMI, smoking status, physical
activity, parity and OC-use (model II and model III). We evaluated whether the GGT-breast
cancer relationship was modified by age, BMI, smoking status and alcohol status by testing
interaction effects in the respective Cox models. The proportional hazards assumption was
checked using Schoenfeld residuals and visual inspection of the hazard plots. The visual inspec-
tion revealed proportionality of hazard functions. Results of significance testing on Schoenfeld
residuals showed that the proportional hazard assumption was fulfilled for each covariate
included in the Cox models (all p-values>0.05).
In the Malmoe cohort, cross-sectional covariates of GGT with established and potential risk
factors for breast cancer were evaluated using a multiple linear regression model. GGT as a
dependent variable was log-transformed in this analysis. Binary predictor variables were
included as 0/1 indicator variables (0 = no, 1 = yes) into the multiple linear regression analysis.
Alcohol consumption was estimated on the basis of a questionnaire in the Malmoe cohort.
Several questions addressed self-reported alcohol consumption. The question “Do you mainly
drink alcohol at weekends or public holidays” showed a high degree of completeness and valid-
ity due to the indirect way of questioning and was therefore selected for analysis. All statistical
analyses were conducted using IBM SPSS 20.0 statistical software.
Results
Characteristics of study population
Demographic and clinical characteristics of the study population are shown in Table 1. The
Vorarlberg cohort comprised of 97,268 women, the Malmoe cohort of 9,790 women, respec-
tively. Median follow-up time was 16.7 years with a total of 1,497,730 person-years at risk and
24.3 years with a total of 219,789 person-years at risk in the Vorarlberg and the Malmoe cohort,
respectively. In the Vorarlberg cohort 2,436 (2.5%) women and in the Malmoe cohort 761
women (7.8%) developed breast cancer in the course of follow-up.
Median GGT level was 18 U/L and 17 U/L in the Vorarlberg and the Malmoe cohort,
respectively. Mean age at study entry was 41 (±16) years and 49 (± 7) years in the Vorarlberg
and Malmoe cohort, respectively. Median body mass index (BMI) was similar in both cohorts
(23.3 kg/m2 in the Vorarlberg and 23.6 kg/m2 in the Malmoe cohort). Smoking status was
available in both cohorts, distinguishing between never, former, and current smokers in 77.8%,
3.3% and 18.9% in the Vorarlberg cohort and in 44.4%, 21% and 34.6% in the Malmoe cohort,
respectively.
Crude and adjusted risk estimates of breast cancer incidence
The crude (univariate model) and adjusted risk (multivariate model I) estimates of breast can-
cer incidence in the pooled Vorarlberg and Malmoe cohort are shown in Table 2. The GGT lev-
els for quartiles 1, 2, 3, and 4 were 13, 14–17, 18–25 and 26 U/L, respectively. In univariate
analysis stratified for cohort a statistically significant increase in risk for breast cancer was seen
in woman with GGT-levels between 18–25 U/L (quartile 3) and 26 (quartile 4) compared to
the reference GGT level of13 U/L (quartile 1), respectively (HR 1.39, 95% CI 1.25 to 1.54 for
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quartile 3; HR 1.76, 95% CI 1.59 to 1.94 for quartile 4; p<0.001). In multivariate analysis
(adjusted for the established breast cancer risk factors age, BMI and smoking status; stratified
Table 1. Characteristics of the Vorarlberg and the Malmoe cohort and of the pooled study population.
Study population Vorarlberg Malmoe Total
N (%) Mean (± SD); Median N (%) Mean (± SD); Median N (%) Mean (± SD); Median
Participants 97,268 9,790 107,058
Follow-up (years) 97,268 15.4 (± 6.4); 16.7 9,790 22.5 (±7.8); 24.3 107,058 16.1 (±6.8); 17.5
Total person-years at risk 1,497,730 219,789 1,717,519
GGT (units/L, based on 37°C) 97,268 24 (±33); 18 9,790 24 (±30); 17 107,058 24 (±33); 17
Age (completed years) 97,268 41 (±16); 38 9,790 49 (±7); 52 107,058 42 (±15); 40
Body mass index (kg/m2) 97,242 24.3 (±4.7); 23.3 9,787 24.4 (±4.3); 23.6 107,029 24.3 (±4.6); 23.3
Smoking status*
Never 75,654 (77.8) 4,095 (44.4) 79,749 (74.9)
Former 3,192 (3.3) 1,941 (21) 5,133 (4.8)
Current 18,422 (18.9) 3,191 (34.6) 21,613 (20.3)
Physical activity*
No n.a. 2198 (22.5) 2198 (22.5)
Yes n.a. 7555 (77.5) 7555 (77.5)
Parity*
0 n.a. 1152 (11.8) 1152 (11.8)
1 n.a. 6023 (61.8) 6023 (61.8)
OC-use*
No n.a. 8841 (90.7) 8841 (90.7)
Yes n.a. 908 (9.3) 908 (9.3)
Alcohol consumption**
No n.a. 7,301 (75.8) 7,301 (75.8)
Yes n.a. 2,325 (24.2) 2,325 (24.2)
Work status*
Unemployed / retired 30,465 (33.6) 4,255 (59.3) 34,720 (35.5)
Employed 60,189 (66.4) 2,917 (40.7) 63,106 (64.5)
Work type*
Manual 33,458 (40.2) 4.067 (46.9) 37,525 (40.8)
Non-manual 49,800 (59.8) 4,603 (53.1) 54,403 (59.2)
Civil status*
Single 16,299 (17.4) 889 (9.1) 17,188 (16.6)
Married 59,787 (63.8) 6,699 (68.6) 66,486 (64.2)
Divorced 7,450 (7.9) 1,689 (17.3) 9,139 (8.8)
Widowed 10,205 (10.9) 483 (4.9) 10,688 (10.3)
Status end of FU
Breast cancer 2,436 (2.5) 761 (7.8) 3,197 (3)
Censored other cancer 6,042 (6.2) 1,820 (18.6) 7,862 (7.3)
Censored death 7,273 (7.5) 914 (9.3) 8,187 (7.6)
Censored loss to FU 0 (0) 135 (1.4) 135 (1.4)
Censored end of study 81,517 (83.8) 6,160 (62.9) 87,677 (81.9)
SD standard deviation, y years, kg kilograms, m2 square meters, °C degrees Celsius, FU follow-up, L Litres, n.a. not available
* Numbers do not add to total N because of missing values
** Alcohol consumption based on question”Do you mainly drink alcohol at weekends or public holidays?”
doi:10.1371/journal.pone.0149122.t001
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by cohort), women with GGT levels of26 U/L (quartile 4) were at significantly higher risk for
breast cancer compared to the quartile 1 GGT-group (HR 1.21, 95% CI 1.09 to 1.35; p = 0.005).
In the Malmoe but not in the Vorarlberg cohort, data on alcohol consumption were avail-
able. Table 3 shows adjusted risk estimates of breast cancer incidence in the Malmoe cohort
adjusted for age, BMI, smoking status, physical activity, parity and OC-use (multivariate model
II) and additionally adjusted for alcohol (multivariate model III).
A statistically significant and almost identical increase in risk for breast cancer was seen in
women with GGT-levels26 U/L (quartile 4) compared to women with GGT levels13 U/L
(quartile 1) in both multivariate models showing almost identical hazard ratios and confidence
intervals when excluding or including alcohol consumption (HR 1.39, 95% CI 1.13–1.71,
p = 0.004 for model II; HR 1.37, 95% CI 1.11–1.69, p = 0.006 for model III).
In both analyses, pooled and Malmoe cohort only, there were no statistically significant
interactions (all p-values for interactions>0.05) in the relationship of GGT with breast cancer
incidence regarding age, BMI, smoking status, alcohol consumption and menopausal status
(age groups i.e.< 50 or> 50 were used as proxy for menopausal status).
Cross-sectional correlates of GGT with breast cancer risk factors
Women in the Malmoe Cohort have filled in a detailed questionnaire on anamnestic data cov-
ering a high number of established breast cancer risk factors and other parameters at the time
Table 2. Crude (univariate model) and adjusted risk (multivariate model I) estimates of breast cancer incidence in the pooled Vorarlberg and Mal-
moe cohort.
GGT levels Breast cancer incidence, N (%) Univariate model, HR (95% CI) Multivariate model I, HR (95% CI)
Quartile 1* (13 U/L) 649 (2.2%) Reference Reference
Quartile 2* (14–17 U/L) 601 (2.5%) 1.10 (0.99 to 1.23) 1.02 (0.91 to 1.14)
Quartile 3* (18–25 U/L) 890 (3%) 1.39 (1.25 to 1.54) 1.11 (1 to 1.24)
Quartile 4* (26 U/L) 921 (3.8%) 1.76 (1.59 to 1.94) 1.21 (1.09 to 1.35)
p for trend (GGT) < 0.001 0.005
CI confidence interval, HR hazard ratio, GGT γ-Glutamyltransferase, U/L units/Litre
Univariate model stratified by cohort. Multivariate model I adjusted for age, body mass index and smoking status stratified by cohort.
*Quartile size: Quartile 1 27.8%, Quartile 2 22.3%, Quartile 3 27.6%, Quartile 4 22.3%
doi:10.1371/journal.pone.0149122.t002
Table 3. Adjusted risk estimates of breast cancer incidence in the Malmoe cohort (multivariate model II) adjusted additionally for alcohol con-
sumption (multivariate model III).
GGT levels Breast cancer incidence, N (%) Multivariate model II, HR (95% CI) Multivariate model III, HR (95% CI)
Quartile 1* (13 U/L) 649 (2.2%) Reference Reference
Quartile 2* (14–17 U/L) 601 (2.5%) 1.11 (0.90 to 1.36) 1.01 (0.89 to 1.35)
Quartile 3* (18–25 U/L) 890 (3.0%) 1.09 (0.88 to 1.36) 1.08 (0.87 to 1.35)
Quartile 4* (26 U/L) 921 (3.8%) 1.39 (1.13 to 1.71) 1.37 (1.11 to 1.69)
Alcohol consumption **
No 523 (6.7%) Reference
Yes 205 (8.2%) 1.19 (1.01 to 1.41)
p for trend (GGT) 0.004 0.006
CI confidence interval, HR hazard ratio, GGT γ-Glutamyltransferase, U/L units/Litre. Model II adjusted for age, body mass index, smoking status, physical
activity, parity, and oral contraceptive-use; Malmoe cohort only. Model III adjusted for age, body mass index, smoking status, physical activity, parity, oral
contraceptive-use and alcohol consumption; Malmoe cohort only
*Quartile size: Quartile 1 29.1%, Quartile 2 25.3%, Quartile 3 22.3%, Quartile 4 23.3%
** Questionnaire issue: “Do you mainly drink alcohol at weekends or public holidays?”
doi:10.1371/journal.pone.0149122.t003
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point of cohort inclusion. Significant correlations found between anamnestic parameters and
GGT levels in the Malmoe cohort are shown in Table 4. High GGT levels were significantly
associated with high age (p<0.001), high BMI (p<0.001), current or former smoking status
(p<0.001), oral contraception use (p<0.001), alcohol consumption (p<0.001) and treatment
for nervous and mental disorders (p = 0.02). A statistically significant, inverse correlation was
seen between GGT levels and physical activity (p = 0.001) and parity (p = 0.008), respectively.
Discussion
The present study investigates the relationship between GGT and breast cancer risk in a large-
scale population-based pooled cohort study considering established breast cancer risk factors
including life style related parameters. Our data suggest a statistically significant association
between GGT and the development of breast cancer, persisting after adjustment for several
confounding factors under different modeling strategies during a median follow-up period of
17.5 years. Importantly, GGT remained an independent risk factor for breast cancer when
adjusting for alcohol intake. In clinical routine, GGT values below 36 U/L are considered nor-
mal, discriminating between normal low (<17.99 U/L) and normal high values (18–35.99 U/L)
[20, 21]. Notably, our multivariate models identified GGT values in the range of 26 U/L sig-
nificantly increased breast cancer risk.
Table 4. Multiple linear regression of GGT-levels in logarithmic units with established risk factors for breast cancer and other anamnestic parame-
ters in the Malmoe cohort for complete cases (n = 6441).
Risk factor / Descriptive statistics N (%), Mean (± SD) Standardized Beta p-value
Age in completed years 51.7 (±4.5) 0.222 <0.001
Body mass index (kg/m2) 24.8 (±4.3) 0.086 <0.001
Smoking status* 0.091 <0.001
No 4,430 (66.7%)
Yes 2,211 (33.3%)
Physical activity*** -0.038 0.001
No 1,700 (25.6%)
Yes 4,941 (74.4%)
Parity -0.032 0.008
Nulliparous 1,076 (16.2%)
Other 5,565 (83.8%)
Oral contraceptive use 0.075 <0.001
No 6,326 (95.3%)
Yes 315 (4.7%)
Alcohol consumption** 0.067 <0.001
No 5,032 (75.8%)
Yes 1,609 (24.2%)
Treatment for nervous or mental disorders 0.028 0.02
No 5,708 (86%)
Yes 933 (14%)
Categorical variables were included as 0/1 coded indicator variables into the regression model.
* Questionnaire issue: “Do you smoke or have you been smoking?”
** Questionnaire issue: “Do you mainly drink alcohol at weekends or public holidays?”
*** Questionnaire issue: “Are you aerobic physical active at least for 150 minutes (moderate-intensive) or at least for 75 minutes (vigorous-intensive) or
an equivalent combination of moderate- to vigorous-intensive active per week?”
doi:10.1371/journal.pone.0149122.t004
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Only two previous studies have specifically focused on the relationship of serum GGT-levels
with the site-specific risk of breast cancer [13, 14].
Fentiman et al. prospectively followed a relatively small cohort of 1,083 healthy women in
Guernsey UK [13]. During the follow-up 96 women developed breast cancer. They found a
highly significant relationship between GGT and breast cancer risk with hazard ratios of>2
for quartiles three and four in comparison to quartile one in a multivariate model. The present
large population-based investigation in more than 107,000 women and 3,179 incident breast
cancer cases confirms their finding that serum-GGT level is a significant risk factor for breast
cancer. Fentiman et al. observed this association only in premenopausal women, whereas we
did not see a significant interaction between GGT and breast cancer incidence with respect to
menopausal status when using age groups as a proxy. The multivariate breast cancer model in
the Fentiman study considered the breast cancer risk factors age, age at menarche, age at first
birth/nulliparity, height and weight. However, classic lifestyle risk factors such as, smoking,
physical activity or alcohol consumption were unknown [13].
Van Hemelrijck et al. studied the association of GGT with increased risk of overall cancer
incidence and several site-specific malignancies in women and men in a large Swedish cohort
(AMORIS study) [14]. They showed a significant association of GGT levels with increased inci-
dence of pooled female malignancies (combined breast and female genital malignancies). In a
site-specific subanalysis in 5626 incident breast cancer cases adjusted for age, socio-economic
status and history of circulatory disease, a significant association between GGT and breast can-
cer risk was seen. The risk was more pronounced in women with high blood glucose compared
to normal blood glucose levels. One can speculate that high glucose levels in these women were
indicative for obesity. The combined effect of two risk factors may explain the higher individual
risk for breast cancer development. However, BMI and other classic breast cancer risk factors
were unknown in this study [14].
In contrast to previous studies, the present study independently evaluates GGT and breast
cancer risk considering in particular life-style factors. We addressed the question, whether ele-
vated serum GGT levels reflect independently an increased risk for breast cancer beyond the
risk factor alcohol. Our data clearly suggest a role of GGT in breast cancer carcinogenesis
beyond alcohol intake. Fentiman et al. state that the blood samples in their study were collected
between 1986 and 1990 before there was a major increase in alcohol use in women [13]. Van
Hemelrijck et al. indirectly accounted for liver dysfunction by stratifying the association
between GGT and cancer risk by alanine aminotransferase (ALT) levels. The liver enzyme ALT
is a specific biomarker for liver damage. Stratified analysis did not show any difference by ALT
levels, suggesting that GGT has an independent role in cancer risk form liver dysfunction [14].
The study of Tsuboya et al. specifically investigated the effect of alcohol consumption on the
relationship between GGT levels and overall-/site-specific cancer incidence in a Japanese
cohort of 15,032 participants (thereof 8,659 women) [22]. Among participants in the highest
quartile, a significant association between GGT and overall cancer incidence independent of
alcohol consumption was found in a multivariate model. In cancer-site specific subanalyses,
GGT remained an alcohol-independent risk factor for colorectal and liver cancer. In other alco-
hol-related cancers such as breast, pancreatic and oesophageal cancer, but not in non-alcohol-
related cancer sites, GGT hazard ratios where increased but did not reach statistical signifi-
cance. Tsuboya et al. concluded that the positive associations seen in alcohol-related cancers
might possibly be due to residual confounding by alcohol [22]. They found their hypothesis
supported by the finding that a positive trend for an association between GGT and overall can-
cer incidence was observed in current drinkers, but not in ever drinkers. However, previous
findings in the Vorarlberg cohort and the AMORIS study strongly speak against this theory,
showing a significant impact of GGT on cancer incidences unrelated to alcohol consumption
γ-Glutamyltransferase and Breast Cancer Risk
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such as malignancies of the respiratory system/intrathoracic organs, urinary organs, male geni-
tal organs and hematologic malignancies in women [11, 12, 14]. An independent role of GGT
in carcinogenesis is also in line with experimental models suggesting a more general causative
of GGT with carcinogenesis [3, 4]. Finally, when focusing on GGT and breast cancer, it is note-
worthy that data in the study of Tsuboya et al. are based on only 71 incident breast cancer cases
among 8,659 women [22]. This possibly also reflects the well-known lower breast cancer rate
of Japanese women compared to women inWestern countries. Together with the fact that alco-
hol tolerability also differs in the Asian and European population [23], the comparability of
data might be jeopardized and separate studies are warranted.
The exact underlying mechanism linking GGT to carcinogenesis is unclear. Traditionally,
GGT and GSH have been regarded as essential components of the cell’s defence apparatus
against oxidative stress [1]. However, the dysregulation of GGT in several tumours raised the
question whether increased GGT expression itself has an active role in neoplastic transforma-
tion [24]. Experimental evidence has elucidated the ability of GGT to modulate crucial redox-
sensitive functions, such as antioxidant defenses and cellular proliferative and apoptotic bal-
ance [24, 25]. The presence of elevated GGT levels seems to reflect a state of persistent oxida-
tive stress as part of the biological pathway related to cancer development [26, 27].
Furthermore, in clinical studies a pivotal role of GGT in tumour invasion, progression and
drug resistance has repeatedly been suggested [2–4, 28].
A major strength of the present study lies in the consideration of established breast cancer
risk factors and in the prospective evaluation of GGT in a large number of women with partic-
ular long time follow-up. However, detailed information on some risk factors, including e.g.
alcohol consumption and physical activity, were available only in the Malmoe cohort, which is
a clear limitation of our study. Furthermore some other confounding factors, e.g. hormone
replacement therapies, were completely missing.
Conclusions
In summary, this is the first study evaluating GGT for site-specific risk of breast cancer in a
large cohort of women considering established breast cancer risk factors including alcohol
intake. Our data clearly confirm GGT as a significant risk factor for breast cancer and suggest a
role in breast cancer carcinogenesis independent of alcohol consumption.
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